1337 related articles for article (PubMed ID: 32470563)
21. Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.
Laprairie RB; Bagher AM; Kelly ME; Denovan-Wright EM
Mol Pharmacol; 2016 Mar; 89(3):364-75. PubMed ID: 26700564
[TBL] [Abstract][Full Text] [Related]
22. Molecular Targets of the Phytocannabinoids: A Complex Picture.
Morales P; Hurst DP; Reggio PH
Prog Chem Org Nat Prod; 2017; 103():103-131. PubMed ID: 28120232
[TBL] [Abstract][Full Text] [Related]
23. Cannabidiol inhibits sucrose self-administration by CB1 and CB2 receptor mechanisms in rodents.
Bi GH; Galaj E; He Y; Xi ZX
Addict Biol; 2020 Jul; 25(4):e12783. PubMed ID: 31215752
[TBL] [Abstract][Full Text] [Related]
24. Cannabigerol Action at Cannabinoid CB
Navarro G; Varani K; Reyes-Resina I; Sánchez de Medina V; Rivas-Santisteban R; Sánchez-Carnerero Callado C; Vincenzi F; Casano S; Ferreiro-Vera C; Canela EI; Borea PA; Nadal X; Franco R
Front Pharmacol; 2018; 9():632. PubMed ID: 29977202
[TBL] [Abstract][Full Text] [Related]
25. Regulation of Expression of Cannabinoid CB
Lillo J; Raïch I; Silva L; Zafra DA; Lillo A; Ferreiro-Vera C; Sánchez de Medina V; Martínez-Orgado J; Franco R; Navarro G
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077095
[No Abstract] [Full Text] [Related]
26. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.
Gamage TF; Barrus DG; Kevin RC; Finlay DB; Lefever TW; Patel PR; Grabenauer MA; Glass M; McGregor IS; Wiley JL; Thomas BF
Pharmacol Biochem Behav; 2020 Jun; 193():172918. PubMed ID: 32247816
[TBL] [Abstract][Full Text] [Related]
28. Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB
Ryalls B; Patel M; Sparkes E; Banister SD; Finlay DB; Glass M
Biochem Pharmacol; 2024 Apr; 222():116052. PubMed ID: 38354957
[TBL] [Abstract][Full Text] [Related]
29. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism.
Hill TD; Cascio MG; Romano B; Duncan M; Pertwee RG; Williams CM; Whalley BJ; Hill AJ
Br J Pharmacol; 2013 Oct; 170(3):679-92. PubMed ID: 23902406
[TBL] [Abstract][Full Text] [Related]
30. A potential role for cannabinoid receptors in the therapeutic action of fenofibrate.
Priestley RS; Nickolls SA; Alexander SP; Kendall DA
FASEB J; 2015 Apr; 29(4):1446-55. PubMed ID: 25550466
[TBL] [Abstract][Full Text] [Related]
31. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
Ashton JC; Wright JL; McPartland JM; Tyndall JD
Curr Med Chem; 2008; 15(14):1428-43. PubMed ID: 18537620
[TBL] [Abstract][Full Text] [Related]
32. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen.
Prather PL; FrancisDevaraj F; Dates CR; Greer AK; Bratton SM; Ford BM; Franks LN; Radominska-Pandya A
Biochem Biophys Res Commun; 2013 Nov; 441(2):339-43. PubMed ID: 24148245
[TBL] [Abstract][Full Text] [Related]
33. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis.
Wilkinson JD; Williamson EM
J Dermatol Sci; 2007 Feb; 45(2):87-92. PubMed ID: 17157480
[TBL] [Abstract][Full Text] [Related]
34. Virtual screening using docking and molecular dynamics of cannabinoid analogs against CB
Aviz-Amador A; Contreras-Puentes N; Mercado-Camargo J
Comput Biol Chem; 2021 Dec; 95():107590. PubMed ID: 34700256
[TBL] [Abstract][Full Text] [Related]
35. Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.
Gamage TF; Farquhar CE; Lefever TW; Marusich JA; Kevin RC; McGregor IS; Wiley JL; Thomas BF
J Pharmacol Exp Ther; 2018 May; 365(2):437-446. PubMed ID: 29549157
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors.
Brizzi A; Brizzi V; Cascio MG; Bisogno T; Sirianni R; Di Marzo V
J Med Chem; 2005 Nov; 48(23):7343-50. PubMed ID: 16279794
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological actions of cannabinoids.
Pertwee RG
Handb Exp Pharmacol; 2005; (168):1-51. PubMed ID: 16596770
[TBL] [Abstract][Full Text] [Related]
38. The tamoxifen derivative ridaifen-B is a high affinity selective CB
Franks LN; Ford BM; Fujiwara T; Zhao H; Prather PL
Toxicol Appl Pharmacol; 2018 Aug; 353():31-42. PubMed ID: 29906493
[TBL] [Abstract][Full Text] [Related]
39. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.
Valdeolivas S; Satta V; Pertwee RG; Fernández-Ruiz J; Sagredo O
ACS Chem Neurosci; 2012 May; 3(5):400-6. PubMed ID: 22860209
[TBL] [Abstract][Full Text] [Related]
40. Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling.
Börner C; Smida M; Höllt V; Schraven B; Kraus J
J Biol Chem; 2009 Dec; 284(51):35450-60. PubMed ID: 19858202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
